Article
Complete response of metastatic microsatellite-stable BRAF V600E colorectal cancer to first-line oxaliplatin-based chemotherapy and immune checkpoint blockade.
Oncoimmunology - 1 Jan 2024
Ree Anne Hansen, Høye Eirik, Esbensen Ying, Beitnes Ann-Christin R, Negård Anne, Bernklev Linn, Tetlie Linn Kruse, Fretland Åsmund A, Hamre Hanne M, Kersten Christian, Hofsli Eva, Guren Marianne G, Sorbye Halfdan, Nilsen Hilde L, Flatmark Kjersti, Meltzer Sebastian
Abstract excerpt
The randomized METIMMOX trial (NCT03388190) examined if patients with previously untreated, unresectable abdominal metastases from microsatellite-stable (MSS) colorectal cancer (CRC) might benefit from potentially immunogenic, short-course oxaliplatin-based chemotherapy alternating with immune checkpoint blockade (ICB). Three of 38 patients assigned to this experimental treatment had metastases from BRAF-mutant...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.